(Q34745582)

4 August 2017

1 reference

title

Medical therapy for ulcerative colitis. (English)

1 reference

4 August 2017

Niraj Jani

1

1 reference

PubMed ID

12122729

4 August 2017

Miguel D Regueiro

series ordinal

2

1 reference

4 August 2017

1 March 2002

1 reference

Gastroenterology Clinics of North America

4 August 2017

1 reference

4 August 2017

31

1 reference

4 August 2017

147-166

1 reference

4 August 2017

1

1 reference

An experiment to determine the active therapeutic moiety of sulphasalazine

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Low-dose oral methotrexate in refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

The efficacy of tobramycin in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Ulcerative colitis and Escherichia coli with adhesive properties

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

A meta-analysis of the role of smoking in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Pantothenic acid, coenzyme A, and human chronic ulcerative and granulomatous colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Inflammatory bowel disease: etiology and pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Sulfasalazine. Multiplicity of action

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Azathioprine hypersensitivity reaction in a patient with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Nicotine enemas for active ulcerative colitis--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Oxidants and free radicals in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Outcome of ulcerative colitis after treatment with transdermal nicotine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Nicotine treatment for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis: investigation by laminar flow bioassay and radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Intensive intravenous treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Review article: immunosuppressive therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

The clinical pharmacology of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Oral tobramycin in ulcerative colitis: effect on maintenance of remission.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

In-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Systemic corticosteroid therapy of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Review article: topical corticosteroids in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active Proctocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

A Controlled Comparison of Corticotropin and Hydrocortisone in the Treatment of Severe Proctocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

1 reference

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Transdermal nicotine for active ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

The colonic epithelium in ulcerative colitis: an energy-deficiency disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

High-dose methylprednisolone in the treatment of active ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Maintenance therapy in ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Enteric Microflora in IBD: Pathogens or Commensals?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Topical treatment of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Corticosteroids: clinical pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Transdermal nicotine as maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Intensive intravenous regimen for severe attacks of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Cortisone and corticotrophin in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Transdermal nicotine inhibits interleukin 2 synthesis by mononuclear cells derived from healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Fecal lactate and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Short-chain fatty acid topical treatment in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Inhibition of human leukocyte elastase activity by heparins: influence of charge density

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Verocytotoxin-producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Effect of nicotine on rectal mucus and mucosal eicosanoids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2801%2900010-3

7 January 2021

10.1016/S0889-8553(01)00010-3

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12122729